Furthermore, in January 2025, the FDA approved semaglutide (Ozempic®) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024). Here, GLP1R is linked to chronic kidney disease.